These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 12075819)
1. Immunomodulator tuftsin augments anti-fungal activity of amphotericin B against experimental murine candidiasis. Masood AK; Faisal SM; Haque W; Owais M J Drug Target; 2002 May; 10(3):185-92. PubMed ID: 12075819 [TBL] [Abstract][Full Text] [Related]
2. Use of tuftsin bearing nystatin liposomes against an isolate of Candida albicans showing less in vivo susceptibility to amphotericin B. Khan MA; Syed FM; Nasti HT; Saima Dagger K; Haq W; Shehbaz A; Owais M J Drug Target; 2003 Feb; 11(2):93-9. PubMed ID: 12881195 [TBL] [Abstract][Full Text] [Related]
3. Co-administration of immunomodulator tuftsin and liposomised nystatin can combat less susceptible Candida albicans infection in temporarily neutropenic mice. Khan MA; Nasti TH; Saima K; Mallick AI; Firoz A; Wajahul H; Ahmad N; Mohammad O FEMS Immunol Med Microbiol; 2004 Jul; 41(3):249-58. PubMed ID: 15196575 [TBL] [Abstract][Full Text] [Related]
4. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model. Khan MA; Owais M J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592 [TBL] [Abstract][Full Text] [Related]
5. Tuftsin-mediated immunoprophylaxis against an isolate of Aspergillus fumigatus shows less in vivo susceptibility to amphotericin B. Khan MA; Ahmad N; Moin S; Mannan A; Wajahul H; Pasha ST; Khan A; Owais M FEMS Immunol Med Microbiol; 2005 Jun; 44(3):269-76. PubMed ID: 15907448 [TBL] [Abstract][Full Text] [Related]
6. Prophylactic use of liposomized tuftsin enhances the susceptibility of Candida albicans to fluconazole in leukopenic mice. Khan MA; Khan A; Owais M FEMS Immunol Med Microbiol; 2006 Feb; 46(1):63-9. PubMed ID: 16420598 [TBL] [Abstract][Full Text] [Related]
7. Immunomodulator tuftsin increases the susceptibility of Cryptococcus neoformans to liposomal amphotericin B in immunocompetent BALB/c mice. Khan MA; Owais M J Drug Target; 2005 Aug; 13(7):423-9. PubMed ID: 16308211 [TBL] [Abstract][Full Text] [Related]
8. Prophylactic role of immunomodulators in treatment of systemic candidiasis in leukopenic mice. Khan MA; Firoz A; Jabeen R; Mohammad O J Drug Target; 2004; 12(7):425-33. PubMed ID: 15621667 [TBL] [Abstract][Full Text] [Related]
9. Immunomodulator tuftsin augments antifilarial activity of diethylcarbamazine against experimental brugian filariasis. Owais M; Misra-Bhattacharya S; Haq W; Gupta CM J Drug Target; 2003 May; 11(4):247-51. PubMed ID: 14578113 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of combination immunotherapy of IgM MAb B6.1 and amphotericin B against disseminated candidiasis. Han Y Int Immunopharmacol; 2010 Dec; 10(12):1526-31. PubMed ID: 20840836 [TBL] [Abstract][Full Text] [Related]
11. Incorporation of amphotericin B in tuftsin-bearing liposomes showed enhanced efficacy against systemic cryptococcosis in leucopenic mice. Khan MA; Nasti TH; Owais M J Antimicrob Chemother; 2005 Oct; 56(4):726-31. PubMed ID: 16126780 [TBL] [Abstract][Full Text] [Related]
12. Comparison of antifungal efficacies of moxifloxacin, liposomal amphotericin B, and combination treatment in experimental Candida albicans endophthalmitis in rabbits. Deren YT; Ozdek S; Kalkanci A; Akyürek N; Hasanreisoğlu B Can J Microbiol; 2010 Jan; 56(1):1-7. PubMed ID: 20130687 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of an oral and tropically stable lipid-based formulation of Amphotericin B (iCo-010) in an experimental mouse model of systemic candidiasis. Ibrahim F; Sivak O; Wasan EK; Bartlett K; Wasan KM Lipids Health Dis; 2013 Oct; 12():158. PubMed ID: 24164705 [TBL] [Abstract][Full Text] [Related]
14. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B. Smith PJ; Olson JA; Constable D; Schwartz J; Proffitt RT; Adler-Moore JP J Antimicrob Chemother; 2007 May; 59(5):941-51. PubMed ID: 17400589 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of renal toxicity and antifungal activity of free and liposomal amphotericin B following a single intravenous dose to diabetic rats with systemic candidiasis. Wasan KM; Conklin JS Antimicrob Agents Chemother; 1996 Aug; 40(8):1806-10. PubMed ID: 8843285 [TBL] [Abstract][Full Text] [Related]
16. Synergic effect of grape seed extract with amphotericin B against disseminated candidiasis due to Candida albicans. Han Y Phytomedicine; 2007 Nov; 14(11):733-8. PubMed ID: 17913484 [TBL] [Abstract][Full Text] [Related]
17. Synergic anticandidal effect of epigallocatechin-O-gallate combined with amphotericin B in a murine model of disseminated candidiasis and its anticandidal mechanism. Han Y Biol Pharm Bull; 2007 Sep; 30(9):1693-6. PubMed ID: 17827722 [TBL] [Abstract][Full Text] [Related]
18. Novel oral amphotericin B formulation (iCo-010) remains highly effective against murine systemic candidiasis following exposure to tropical temperature. Wasan KM; Sivak O; Bartlett K; Wasan EK; Gershkovich P Drug Dev Ind Pharm; 2015; 41(9):1425-30. PubMed ID: 25170660 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of antifungal pharmacodynamic characteristics of AmBisome against Candida albicans. Takemoto K; Yamamoto Y; Ueda Y Microbiol Immunol; 2006; 50(8):579-86. PubMed ID: 16924142 [TBL] [Abstract][Full Text] [Related]
20. Treatment of a murine model of systemic candidiasis with liposomal amphotericin B bearing antibody to Candida albicans. Hospenthal D; Gretzinger K; Rogers A J Med Microbiol; 1989 Nov; 30(3):193-7. PubMed ID: 2685314 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]